2022-000049-34
A Phase 2 double blind, randomized, placebo controlled study evaluating the effect of SAR443820 on serum neurofilament levels in participants with multiple sclerosis, followed by an open label long-term extension period
SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT·EU Clinical Trials RegisterOngoing
Study focus
- Disease/Condition
- Multiple sclerosis
Sponsor & location
- Primary sponsor
- SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT
- Funder
- Sanofi-Aventis recherche & développement
Timeline & enrollment
- Phase
- N/A
- Start date
- N/A
- End date
- N/A
Primary outcome
Participants are excluded from the study if any of the following criteria apply:
ICD-10 classifications
Multiple sclerosisProgressive systemic sclerosisSystemic sclerosisSystemic sclerosis, unspecifiedDiffuse sclerosis
Data source
- Registry
- EU Clinical Trials Register
- Trial ID
- 2022-000049-34
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for 2022-000049-34 through Pure Global AI's free database. This phase not specified trial is sponsored by SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT and is currently Ongoing. The study focuses on Multiple sclerosis.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to EU Clinical Trials Register data, helping medical device and pharmaceutical companies navigate clinical research efficiently.